Brain-Computer Interface Company Synchron Raises $200M
New York-based Synchron, a brain-computer interface (BCI) company, secured $200 million in Series D funding, increasing its total capital to $345 million. The investment round was led by Double Point Ventures, with ongoing support from ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
New contributors in this round include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
Stentrode BCI Technology
Synchron develops the Stentrode BCI, a non-surgical, endovascular platform aimed at enhancing mobility, communication, and autonomy for people with paralysis. The device is implanted through a catheter-based procedure, interfacing with the motor cortex via blood vessels to capture and convert brain signals into digital commands.
This hands-free technology enables users to operate digital devices without physical interaction. To date, the Stentrode has been implanted in 10 patients across clinical trials in Australia and the United States.
Plans for Fund Utilization
- Accelerate clinical trials and commercial launch of the BCI.
- Expand in-house operations in New York to support its cognitive AI division, which focuses on building models from neural data.
- Grow the engineering hub in San Diego.
"Synchron's Stentrode BCI is a non-surgical endovascular brain-computer interface platform designed to help improve mobility, communication, and independence for individuals with paralysis."
These developments position Synchron at the forefront of advancing brain-computer interface technology to improve patient quality of life.
Author's summary: Synchron raised $200M to boost trials and expand its innovative non-surgical brain-computer interface that supports hands-free digital interaction for paralysis patients.